Status:
COMPLETED
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Lead Sponsor:
Alcon Research
Conditions:
Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
Eligibility Criteria
Inclusion
- Patients with non-proliferative diabetic retinopathy (mild, moderate or severe) and planned cataract extraction by phacoemulsification.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Central subfiled macular thickness greater than or equal to 250 microns
- CME in either eye.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT00782717
Start Date
November 1 2008
End Date
July 1 2010
Last Update
October 26 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.